{"filings":[{"id":974996,"accession_number":"0001193125-26-266040","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2026-06-10T21:08:54+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Tectonic completes enrollment in Phase 2 TX45 trial for PH-HFpEF; topline data expected early Q1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["APEX trial enrolled 191 patients across 14 countries; 72% (137 pts) in enriched CpcPH subset (PVR > 3 WU).","Mean baseline PVR: 4.2 WU overall; 5.2 WU in CpcPH subset.","Topline results from Phase 2 APEX study expected in early Q1 2027.","Two dose regimens of TX45 (300 mg monthly or every other week) vs placebo; primary endpoint is change in PVR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94657,"accession_number":"0001193125-26-212069","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tectonic Therapeutic Q1 net loss $25.2M; TX45 APEX Phase 2 enrollment near complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.2M in Q1 2026 vs. $15.9M in Q1 2025; R&D expense $20.9M (up $7.9M YoY).","Cash $236.9M as of Mar 31, 2026, providing runway into Q4 2028.","TX45 APEX Phase 2 in PH-HFpEF enrollment nearing completion; topline data expected late Q4 2026/early Q1 2027.","TX2100 Phase 1a in HHT ongoing; topline results expected by end of Q3 2026.","Appointed François Nader as Board Chair and Jessica Chutter as independent director."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94656,"accession_number":"0001193125-26-173829","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Tectonic Therapeutic appoints Jessica Chutter to Board of Directors effective June 8, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jessica Chutter appointed to Tectonic's Board and Audit Committee, effective June 8, 2026.","Chutter spent her career at Morgan Stanley, most recently as Vice Chair of Healthcare Investment Banking until February 2026.","She advised on approximately $80B in capital raising and $85B in strategic transactions.","As non-employee director, she receives $40K annual retainer, $7.5K for Audit Committee, and 20,400-share initial option award."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107185,"accession_number":"0001193125-26-076843","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tectonic Q4 net loss $19.2M; TX45 Phase 1b positive, TX2100 Phase 1a started","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $19.2M (vs $12.4M YoY); R&D expenses $16.3M on advancing pipeline.","Cash and equivalents $253.8M as of Dec 31, 2025; expected cash runway into Q4 2028.","TX45 Phase 1b in PH-HFrEF showed 29.2% reduction in PCWP and 17.3% cardiac output improvement.","TX2100 Phase 1a in HHT randomized first subject Feb 2026; topline results expected Q4 2026.","François Nader appointed independent director effective April 1, 2026, to also serve as Board Chair."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107184,"accession_number":"0001193125-26-066964","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Tectonic appoints François Nader as independent director and Chair; McGuire steps down","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["François Nader, M.D., appointed to board effective Apr 1, 2026; assumes Chair role same date.","Current Chair Terry McGuire resigns as Chair Apr 1, remains board member until June 2026 annual meeting.","Nader is independent director at Moderna (MRNA); led multiple biotech acquisitions (Acceleron, Alexion).","Company posted presentation on TX2100 for HHT and bleeding disorders (no new clinical data)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123520,"accession_number":"0001193125-25-269573","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tectonic Q3 net loss $19M; positive TX45 Phase 1b data in PH-HFrEF","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.0M in Q3 2025 vs $17.7M in Q3 2024; R&D expenses $16.9M.","Cash and equivalents $268.4M as of Sept 30, 2025; runway into Q4 2028.","TX45 Part B: 29.2% reduction in PCWP, 17.3% improvement in cardiac output in PH-HFrEF.","TX45 APEX Phase 2 in PH-HFpEF over 50% enrolled; topline results expected in 2026.","TX2100 Phase 1 for HHT to start Q1 2026; TX45 PH-ILD Phase 2 planned in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123519,"accession_number":"0001193125-25-256958","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tectonic Therapeutic reports positive Phase 1b Part B data for TX45 in PH-HFrEF","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single dose of TX45 improved left heart function and pulmonary hemodynamics: PCWP -29.2%, CO +17.3%, mPAP -19.3%, TPR -29.2% mean change.","In CpcPH patients (PVR>3 WU), PVR reduced -19.7%; PVR >2 WU group showed -10.3% mean change.","Echocardiographic improvements at day 29: LVEF +19.4%, RVFAC +20.3%, TAPSE/SPAP +36.3% mean change.","TX45 well tolerated with no serious or severe adverse events, no clinically significant BP changes or immune reactions.","APEX Phase 2 trial in PH-HFpEF ongoing; topline results expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140198,"accession_number":"0001193125-25-175567","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tectonic Therapeutic Q2 net loss $20M; cash $287.4M; TX45 PH-ILD Phase 2 planned 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.0M in Q2 2025 vs $12.7M in Q2 2024; R&D expenses rose to $17.2M from $7.1M.","Cash and cash equivalents $287.4M as of June 30, 2025; expected cash runway into Q4 2028.","TX45 Phase 1b Part A results: 19% reduction in PCWP, 18.5% improvement in cardiac output, >30% PVR reduction in CpcPH.","Part B of TX45 Phase 1b in PH-HFrEF enrollment completed; topline results expected early Q4 2025.","New PH-ILD Phase 2 trial for TX45 to start in 2026; TX2100 Phase 1 expected Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157841,"accession_number":"0001193125-25-137149","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tectonic Therapeutic stockholders elect two Class I directors and ratify Deloitte as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Alise Reicin, M.D. elected director with 14,469,766 votes for and 432,093 withheld.","Praveen Tipirneni, M.D. elected director with 14,452,647 votes for and 449,212 withheld.","Deloitte & Touche LLP ratified as independent auditor for fiscal 2025 (16,249,011 for, 3,867 against).","Advisory vote on executive compensation approved (14,819,757 for, 66,777 against).","Stockholders preferred an annual advisory vote on executive compensation (14,878,746 for 1 year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157840,"accession_number":"0001193125-25-122511","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tectonic TX45 Phase 1b in PH-HFpEF shows 19% PCWP reduction, sustained 29-day effects","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single IV dose of TX45 reduced PCWP by 19.0% [95% CI, -26.1% to -11.9%] in 19-patient cohort.","In CpcPH subgroup (PVR≥2), PVR decreased 32.0% (≥2) and 35.5% (≥3); 30%+ reduction in PVR.","Echocardiogram showed sustained improvements in TAPSE/SPAP and RVFAC for 29 days post-dose.","Cardiac output increased 18.5% overall; greater improvement in patients with higher baseline PVR.","No serious or severe adverse events; Phase 1b Part B in HFrEF topline expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157839,"accession_number":"0000950170-25-066932","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tectonic Q1 net loss $15.9M; cash $306M; TX45 Phase 1b shows PCWP reduction 17.9%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.9M for Q1 2025 vs $15.2M in Q1 2024; R&D expenses $13.0M, G&A $5.3M.","Cash and equivalents $306.2M as of Mar 31, 2025, providing runway into Q4 2028; $185M PIPE closed Feb 2025.","TX45 Phase 1b Part A: 17.9% reduction in PCWP in PH-HFpEF; >30% PVR reduction in CpcPH subgroup.","Full Phase 1b Part A data to be presented May 17, 2025 at ESC Heart Failure Congress.","Part B of TX45 Phase 1b (PH-HFrEF) enrolling; topline expected 2H 2025; APEX Phase 2 data expected 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176224,"accession_number":"0000950170-25-042630","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tectonic reports Q4 2024 net loss $12.4M; positive TX45 Phase 1b interim results","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["TX45 Phase 1b Part A reduced PCWP by 17.9% in PH-HFpEF and PVR >30% in CpcPH subgroup.","Completed ~$185.0M private placement in Feb 2025; cash runway into Q4'28.","Cash and equivalents $141.2M at Dec 31, 2024; Q4 net loss $12.4M vs $7.9M year ago.","APEX Phase 2 trial topline results expected in 2026; Phase 1b Part B results expected 2H'25.","TX2100 Phase 1 initiation expected Q4'25 or Q1'26 for hereditary hemorrhagic telangiectasia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176223,"accession_number":"0001193125-25-018840","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Tectonic raises $185M via PIPE of 3.69M shares to fund clinical pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$185M; 3,689,465 shares at $50.00 (fund investors) and $54.14 (officer/directors).","Expected close Feb 5, 2025; net proceeds for TX45, TX2100, discovery platform, and working capital.","New and existing investors include Adage Capital, Ally Bridge, Deep Track, EcoR1, Farallon, and others.","TD Cowen, Leerink, Piper Sandler, Wells Fargo acted as placement agents; resale registration to be filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176222,"accession_number":"0001193125-25-016224","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"TX45 Phase 1b data show 17.9% PCWP reduction in PH-HFpEF; >30% PVR cut in CpcPH subgroup","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TX45 achieved 17.9% reduction in PCWP (overall population) and >30% reduction in PVR in CpcPH patients.","Cardiac output increased 17.4%; mean pulmonary artery pressure reduced 15.9% across the total study.","No serious/severe adverse events, discontinuations, or significant hypotension; well tolerated.","APEX Phase 2 trial in PH-HFpEF is underway; topline results expected in 2026.","Data support enrichment of CpcPH patients in APEX; Part B of Phase 1b (PH-HFrEF) starts February 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176221,"accession_number":"0001193125-25-005304","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tectonic Therapeutic provides updated corporate presentation; no specific financial or pipeline details in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation dated January 2025 attached as exhibit but not fully reproduced in filing.","Presentation title: Innovating GPCR-Targeted Therapies to Reach Large Untapped Market Opportunities.","No new financial metrics, guidance, or pipeline milestones disclosed in the filing text.","Investors must refer to the external presentation for any material updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193112,"accession_number":"0000950170-24-123411","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tectonic Therapeutic Q3 net loss $17.7M; TX45 Phase 1b enrollment ahead; new HHT candidate TX2100","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.7M for Q3 2024 vs $10.1M a year ago; R&D spend $14.3M (up from $8.1M) on TX45 trials.","Cash $159.1M as of Sept 30, 2024; runway into mid-2027 covering key readouts and HHT program.","Phase 1b hemodynamic trial for TX45 enrollment ahead of plan; topline results expected late Q1 2025/early Q2 2025.","First subject dosed in TX45 APEX Phase 2 trial in Oct 2024; topline data expected 2026.","TX2100 development candidate selected for HHT (no approved therapy); Phase 1 trial expected Q4 2025/Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209490,"accession_number":"0001193125-24-222189","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tectonic reports positive Phase 1a data for TX45; Phase 2 doses selected, Phase 1b dose escalated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1a: TX45 well-tolerated, no immunogenicity, robust PK/PD; Phase 2 doses set at 300 mg SC monthly or every other week.","Phase 1b hemodynamic trial in PH-HFpEF escalated to 3 mg/kg IV; topline results expected Q2 2025.","Phase 2 APEX trial screening initiated; topline results anticipated in 2026.","Full Phase 1a results to be presented at AHA Scientific Sessions November 2024.","Over 600,000 patients estimated with Group 2 PH-HFpEF; no approved treatments currently."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209489,"accession_number":"0001193125-24-200629","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tectonic reports Q2 net loss $12.7M; cash $185.1M; TX45 Phase 2 trial open","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.7M for Q2 2024 vs $10.5M in Q2 2023; R&D expenses $7.1M.","Cash and cash equivalents $185.1M as of June 30, providing runway into mid-2027.","TX45 Phase 2 APEX trial for PH-HFpEF open for screening; first dosing expected Sept 2024.","Closed reverse merger with AVROBIO in June 2024, with concurrent $130.7M private placement.","Appointed Dan Lochner as CFO in June 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209488,"accession_number":"0001193125-24-188881","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tectonic Therapeutic receives FDA IND clearance for lead program TX45 in PH-HFpEF","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for TX45 (Fc-relaxin fusion) for Group 2 PH due to HFpEF, a condition with no approved therapy affecting >600K US patients.","Phase 1a healthy volunteer topline results due September 2024; Phase 1b patient hemodynamic topline results expected mid-2025.","Phase 2 trial to start Q3 2024: 24-week SC dosing, up to 180 subjects; primary endpoint PVR change. Topline results anticipated in 2026.","TX45 engineered for optimized pharmacology targeting vasodilation, diastolic dysfunction, and remodeling to improve exercise capacity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209487,"accession_number":"0001193125-24-175599","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"COO Christian Cortis departs Tectonic Therapeutic; receives 9-month severance and consulting role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Christian Cortis separated as COO effective July 5, 2024, per separation agreement.","Severance includes 9 months of base salary ($300,750.11) plus prorated 2024 target bonus ($70,175.02).","Consulting from July 5, 2024 through March 31, 2025; equity awards continue vesting during consulting period.","Cortis must abide by non-disparagement and confidentiality obligations; company retains right to claw back severance for breach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227561,"accession_number":"0001193125-24-168273","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tectonic Therapeutics details TX45 Phase 2 trial design for Group 2 PH-HFpEF","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 randomized, placebo-controlled, double-blind trial to start H2 2024 globally (US, Europe, Eastern Europe, Australia).","Trial enriches for patients with PVR >3 on right heart catheterization; ~180 subjects expected.","Subjects randomized 1:1:1 to two TX45 doses or placebo; 24-week treatment plus 8-week follow-up.","Goal: evaluate efficacy in combined pre- and post-capillary PH and whole Group 2 PH-HFpEF population."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227560,"accession_number":"0001193125-24-164480","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["2.01","1.01","9.01","5.02","4.01","2.02","3.02","3.03","5.01","5.03","5.06","8.01"],"status":"ready","headline":"Tectonic Therapeutic completes merger with AVROBIO, begins trading as TECX","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger completed on June 20, 2024; AVROBIO merged into Tectonic, which survived as a wholly owned subsidiary.","AVROBIO effected a 1-for-12 reverse stock split and changed its name to Tectonic Therapeutic, Inc.","Shares began trading on Nasdaq under ticker TECX on June 21, 2024, replacing prior symbol AVRO.","Contingent Value Rights (CVRs) issued to AVROBIO stockholders for potential proceeds from legacy assets.","Post-merger ownership: Tectonic securityholders ~75.2%, AVROBIO securityholders ~24.8% on a diluted basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227556,"accession_number":"0001193125-24-163207","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K/A","filed_at":"2024-06-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AVROBIO merger with Tectonic delayed to June 20; 1-for-12 reverse split effective June 20; new ticker TECX","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closing postponed from June 18 to around June 20, 2024.","Stockholders approved reverse split ratio of 1-for-12; effective June 20 at 4:00 p.m. ET.","No fractional shares; cash payment based on closing price prior to effective time.","Common stock to trade on split-adjusted basis under ticker TECX starting June 21, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227559,"accession_number":"0001193125-24-161663","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AVROBIO approves 1-for-12 reverse stock split; merger with Tectonic to close June 18","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Reverse stock split at 1-for-12 ratio effective 4:00 pm ET on June 18, 2024.","Merger with Tectonic anticipated to close on or around June 18, 2024.","Common stock to trade on Nasdaq under ticker TECX starting June 20, 2024.","Fractional shares cashed out based on closing price before the effective time.","Outstanding equity awards under company plans adjusted proportionally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227558,"accession_number":"0001193125-24-159168","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AVROBIO stockholders approve all proposals for merger with Tectonic Therapeutic","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Stock issuance and change-of-control proposal passed: 30,233,557 For, 1,899,576 Against.","Reverse stock split (1:3 to 1:30 range) approved: 29,802,382 For, 2,181,632 Against.","Tectonic 2024 Equity Incentive Plan approved: 25,325,215 For, 6,747,913 Against.","Advisory vote on M&A executive compensation approved: 29,551,916 For, 2,530,022 Against.","Adjournment proposal approved but not needed as stock issuance and reverse split passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227557,"accession_number":"0001193125-24-153749","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AVROBIO voluntarily supplements merger disclosures as three shareholder suits challenge deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three shareholder lawsuits filed in NY state and federal court allege Registration Statement omissions; seek to enjoin merger.","Eleven demand letters also received; AVROBIO denies wrongdoing but voluntarily adds supplemental disclosures.","Supplemental disclosures include revised background of the merger and updated Houlihan Lokey financial analysis tables.","Special stockholder meeting to approve merger with Tectonic scheduled for June 11, 2024.","Company maintains lawsuits are without merit and that existing disclosures comply with law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246384,"accession_number":"0001193125-24-019406","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AVROBIO enters into definitive merger with Tectonic Therapeutic","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["AVRO (AVRO) signs merger agreement with Tectonic; Merger Sub will merge into Tectonic, making it a wholly-owned subsidiary.","Deal announced January 30, 2024; combined company to focus on discovery of novel GPCR-targeted therapies.","Investor webcast and slide presentation available on AVRO's website; closing subject to customary conditions and approvals.","Specific financial terms (deal value, premium, expected close date) not stated in the provided exhibit text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246383,"accession_number":"0001193125-24-018812","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["1.01","5.01","5.02","7.01","9.01"],"status":"ready","headline":"AVROBIO to merge with Tectonic in all-stock deal; $130.7M private financing; combined company targets GPCRs","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pre-merger AVRO holders expected to own ~22.3%; Tectonic holders ~40.2%; financing investors ~37.5% of combined firm.","Concurrent $130.7M private placement from new and existing life sciences investors; combined cash ~$165M at close, runway into mid-2027.","Combined company to advance Tectonic's lead asset TX45 (Fc-relaxin fusion protein) through clinical catalysts.","AVRO stockholders to receive CVRs for contingent payments from future monetization of AVRO's legacy gene therapy assets.","Support agreements from ~88% of Tectonic voting power and ~10.8% of AVRO shares; 180-day lock-up for insiders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281030,"accession_number":"0001140361-23-034121","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2023-07-12T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"AVROBIO halts gene therapy programs, cuts 50% workforce, explores strategic alternatives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved halting all program development; workforce reduction of ~50% expected by end of July 2023.","Estimated severance and termination costs total ~$2.8 million, to be recorded in Q3 2023.","Company to explore strategic alternatives including acquisition, merger, or business combination.","Decision not related to safety or regulatory issues; remaining staff to focus on strategic alternatives and Novartis services.","No timetable for completion; no assurance any transaction will occur."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299729,"accession_number":"0001140361-23-029869","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K/A","filed_at":"2023-06-14T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"AVROBIO amends 8-K: no material charges from cystinosis gene therapy asset sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to prior 8-K (May 22, 2023) regarding sale of cystinosis gene therapy program.","Company had previously been unable to estimate related charges; now determines no material charges expected.","Asset sale includes all assets specifically related to the cystinosis gene therapy program.","No change to other disclosures in the original Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299736,"accession_number":"0001140361-23-029620","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2023-06-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AVROBIO regains Nasdaq minimum bid price compliance; matter closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified AVROBIO on June 12, 2023 that bid price closed at or above $1.00 for 14 consecutive business days.","Prior deficiency notice on May 11, 2023 cited 30 consecutive business days below $1.00 from March 29 to May 10.","Regained compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Global Select Market.","Nasdaq has closed the matter regarding the minimum bid price requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299735,"accession_number":"0001140361-23-029221","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["1.02","2.01","5.02","7.01","9.01"],"status":"ready","headline":"AVROBIO completes $87.5M sale of cystinosis gene therapy program to Novartis; cash runway extended to Q4 2024","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale closed June 9, 2023 for $87.5M cash; proceeds expected to extend cash runway into Q4 2024.","AVROBIO retains full rights to HSC gene therapy programs for Gaucher, Hunter, and Pompe diseases.","Term Loan Facility with Silicon Valley Bank repaid in full and terminated upon closing.","Interim CEO Ostrowski gets base salary increase to $535K, 55% bonus target, and 70,000 RSUs; retention bonuses approved for Ostrowski and CTO Golipour.","Unaudited pro forma shows net loss improved to $23.7M for Q1 2023 and $16.8M for FY2022 including gain on asset sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299734,"accession_number":"0001140361-23-029124","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"AVROBIO approves $250K in transaction bonuses for CEO and CTO tied to cystinosis program sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Transaction bonuses of $150k for President/Interim CEO/CFO Erik Ostrowski and $100k for CTO Azadeh Golipour, payable in three installments after Asset Sale closing.","Bonuses contingent on closing of previously announced sale of cystinosis gene therapy program; forfeiture if resignation/termination before payment.","Stockholders elected directors Ian Clark and Annalisa Jenkins as Class II directors for term until 2026 annual meeting.","Ratification of Ernst & Young as independent auditor for FY2023 with over 34 million votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299733,"accession_number":"0001140361-23-025867","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["1.01","2.05","7.01","9.01"],"status":"ready","headline":"AVROBIO sells cystinosis gene therapy program to Novartis for $87.5M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale of AVR-RD-04 to Novartis for $87.5M cash at closing; proceeds to extend cash runway into Q4 2024.","AVROBIO retains full rights to Gaucher, Hunter, Pompe programs.","Company expects to use ~$16.4M of proceeds to pay off Term Loan Facility with Silicon Valley Bank.","Transaction expected to close by end of Q3 2023, subject to customary conditions.","TD Cowen and Wells Fargo acted as financial advisors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299732,"accession_number":"0001140361-23-025377","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2023-05-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AVROBIO reports positive Phase 1/2 gene therapy data for cystinosis; all patients off oral cysteamine up to 36 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six patients remain off oral cysteamine up to 36 months post gene therapy.","Durable reduction in leukocyte cystine levels; tissue crystals declined below baseline in first 4 patients.","Neurocognitive tests (Beery VMI) show improvement/stabilization up to 36 months, suggesting CNS impact.","No drug-related adverse events or serious adverse events reported to date.","Positive regulatory feedback from FDA and MHRA to align on registration-enabling trial path."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299731,"accession_number":"0001140361-23-024002","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AVROBIO Q1 net loss $25.0M, cash $72.3M; appoints interim CEO; GD3 trial on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.0M for Q1 2023 vs $29.8M in Q1 2022; R&D expenses $17.3M, G&A $7.9M.","Cash and equivalents $72.3M as of March 31, 2023; expected runway into Q1 2024.","Plan to initiate registrational Phase 2/3 trial for Gaucher disease type 3 in H2 2023, subject to regulatory alignment.","Appointed CFO Erik Ostrowski as interim CEO, succeeding Geoff MacKay; board searching for permanent CEO.","Collaborator-sponsored Phase 1/2 trial for Hunter syndrome (MPS-II) initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299730,"accession_number":"0001140361-23-021828","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"AVROBIO CEO Geoff MacKay resigns; CFO Erik Ostrowski named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Geoff MacKay resigns effective May 1, 2023, to join an early-stage company; no disagreement with the company.","CFO Erik Ostrowski appointed President and Interim CEO, effective May 1, 2023; will continue as CFO.","Board of Directors begins search for a permanent CEO; Ostrowski has over 20 years of biotech finance experience.","MacKay served as founding CEO for eight years; company transitioning to late-stage development for Gaucher and cystinosis programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319837,"accession_number":"0001140361-23-013237","cik":1681087,"company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AVROBIO reports Q4 net loss $25.0M, full-year 2022 loss $105.9M; cash $92.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.0M in Q4 2022 vs $28.2M in Q4 2021; full year loss $105.9M vs $119.1M.","R&D expenses $18.1M (Q4) and $72.2M (FY); G&A expenses $7.1M (Q4) and $33.2M (FY).","Cash and equivalents $92.6M as of Dec 31, 2022, down from $189.6M a year earlier; expects to fund operations into Q1 2024.","Plan to initiate registrational global Phase 2/3 trial (Guard3) for Gaucher disease type 3 in H2 2023, subject to regulatory alignment.","Collaborator-sponsored Phase 1/2 trial for cystinosis completed dosing; late-stage activities planned H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":566830365.2290502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}